ERGOMED Announces Launch of its Rare Disease Innovation Center
ERGOMED has announced the establishment of its Rare Disease Innovation Center™.
The Rare Disease Innovation Center™ is a consortium of innovative partners and internal subject matter experts dedicated to developing tailored solutions for rare disease-focused companies and patients.
In addition, ERGOMED has announced new partnerships with Trialbee and mdgroup as part of its new consortium. Trialbee will serve as its patient identification partner and mdgroup will provide patient support servces.
Read more about this announcement by following the links below:
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
